Please assess the completion status of the following clinical trial:

Trial Title: Phase I Dose Finding Study of SSR97225 Given in Patients With Refractory Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of metastatic or locally advanced non-hematological cancer~* Patients with solid tumors refractory to therapy or for whom no therapy exists~Exclusion Criteria:~* Five or more prior chemotherapy lines for metastatic disease~* Eastern Cooperative Oncology Group (ECOG) performance status \>2~* Patients having discontinued previous specific anti-cancer treatment~* Patients who have not recovered from all toxic effects from previous specific anti-cancer treatment (excluding alopecia)~* Patients with abnormal biological/hematological parameters, cardiac abnormalities or serious infection/intercurrent illness likely to jeopardize the patient's safety or the course of the protocol treatment~* No adequate birth control methods~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): 1 hour IV infusion D1
- Arm B (Type: EXPERIMENTAL): 1 hour IV infusion D1, D8, D15

Based on this trial design, predict the completion outcome and termination type (if applicable).